We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
卫生部委员会将考虑lonocotocog alfa和pegunigalsidase alfa用于高成本病种计划。了解纳入对患者的重要性以及出现的障碍。
